The Lynx Group

WCLC 2016 – Lung Cancer

Challenges in Managing Toxicities
Dr. Edward Garon believes it's important to recognize that agents without efficacy are not beneficial to the patient despite low toxicity.
Read Article

My Practice: Roles and Responsibilities
Dr. Edward Garon describes how staff at his practice interacts with patients.
Read Article

Immunotherapies and Lung Cancer
Dr. Edward Garon explains how he discusses immunotherapies with patients.
Read Article

Choosing the Right Therapy for Patients with NSCLC
Dr. Edward Garon shares an anecdote about an interesting NSCLC case from his practice.
Read Article

Differences in NSCLC Patient Populations
Dr. Edward Garon speaks about how differences in patient populations with lung cancer can make it difficult to interpret and act on data.
Read Article

ALK Gene Rearrangement and PD-L1 Expression
Dr. Edward Garon does not believe there is much value in utilizing PD-L1 inhibitors for pateints with ALK gene rearrangement.
Read Article

A Look at PD-1 and PD-L1 Inhibitors
Dr. Edward Garon discusses the use of PD-1 and PD-L1 inhibitors in patients with lung cancer.
Read Article

Shifts in Lung Cancer Treatment
Dr. Edward Garon reviews how certain drugs can change the landscape for treating patients with lung cancer.
Read Article

Common Presenting Factors for NSCLC
Dr. Edward Garon provides an overview of the most common presenting clinical features in adults with non-small cell lung cancer (NSCLC).
Read Article

Who Should be Screened for Lung Cancer?
Dr. Edward Garon identifies the target population for lung cancer screening.
Read Article

Page 1 of 4

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: